Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study)
Open Access
- 26 June 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (6), e0235381
- https://doi.org/10.1371/journal.pone.0235381
Abstract
Despite the availability of effective antimicrobials, tuberculosis (TB) is still a serious health threat. Mortality is even higher in people living with HIV who are diagnosed with TB. New therapies are needed to shorten the time required to cure TB and decrease fatality rates in this population. N-acetylcysteine (NAC) is a glutathione precursor and has shown recently in experimental setting to present in vitro and in vivo anti-mycobacterial activity. We test the hypothesis that NAC is safe, well tolerated and secondarily efficacious as adjunctive anti-TB therapy in hospitalized individuals with HIV-associated TB. Patients were enrolled sequentially in a tertiary care center, in the Brazilian Amazon. We performed a randomized, parallel group, single-center, open study trial of two arms, in hospitalized patients over 18 years of age, with microbiologically confirmed pulmonary TB in HIV: one with rifampicin, isoniazid, pyrazinamide and ethambutol at standard doses (Control Group), and a second in which NAC 600 mg bid for eight weeks was added (NAC Group). A total of 21 and 18 patients were enrolled to the Control Group and NAC Group, respectively. Adverse event rates were similar in the two arms. Our findings suggest that in the more critical population of hospitalized patients with HIV-associated TB, the use of NAC was not unsafe, despite the low sample size, and a potential impact on faster negative cultures needs to be further explored in larger studies.Keywords
Funding Information
- Ministério da Saúde (Interfam)
- FAPEAM (PAPAC)
- FAPEAM (Pró-Estado)
This publication has 26 references indexed in Scilit:
- Culture Conversion Rate at 2 Months of Treatment According to Diagnostic Methods among Patients with Culture-Positive Pulmonary TuberculosisPLOS ONE, 2014
- High-Dose N-Acetylcysteine in Stable COPDChest, 2013
- Glutathione Supplementation Improves Macrophage Functions in HIVJournal of Interferon & Cytokine Research, 2013
- Unveiling the Mechanisms for Decreased Glutathione in Individuals with HIV InfectionClinical and Developmental Immunology, 2011
- Glutathione and Adaptive Immune Responses against Mycobacterium tuberculosis Infection in Healthy and HIV Infected IndividualsPLOS ONE, 2011
- Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicityEuropean Journal of Gastroenterology & Hepatology, 2010
- Glutathione-Redox Balance Regulates c-rel–Driven IL-12 Production in Macrophages: Possible Implications in Antituberculosis ImmunotherapyThe Journal of Immunology, 2010
- High Heritability but Uncertain Mode of Inheritance for Total Serum IgE Level andSchistosoma mansoniInfection Intensity in a Schistosomiasis‐Endemic Brazilian PopulationThe Journal of Infectious Diseases, 2008
- Effect of N-acetyl-L-cysteine on lymphocyte apoptosis, lymphocyte viability, TNF-alpha and IL-8 in HIV-infected patients undergoing anti-retroviral treatmentThe Brazilian Journal of Infectious Diseases, 2004
- N‐acetylcysteine replenishes glutathione in HIV infectionEuropean Journal of Clinical Investigation, 2000